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Summary
Invadopodia are protrusive structures used by tumor cells
for degradation of the extracellular matrix to promote inva-
sion [1]. Invadopodia formation and function are regulated
by cytoskeletal-remodeling pathways and the oncogenic
kinase Src. The guanine nucleotide exchange factor Vav1,
which is an activator of Rho family GTPases, is ectopically
expressed in many pancreatic cancers, where it promotes
tumor cell survival and migration [2, 3]. We have now
determined that Vav1 is also a potent regulator of matrix
degradation by pancreatic tumor cells as depletion of Vav1
by siRNA-mediated knockdown inhibits the formation of
invadopodia. This requires the exchange function of Vav1
toward theGTPase Cdc42, which is required for invadopodia
assembly [4, 5]. In addition, we have determined that Src-
mediated phosphorylation and activation of Vav1 are both
required for, and, unexpectedly, sufficient for, invadopodia
formation. Expression of Vav1 Y174F, which mimics its acti-
vated state, is a potent inducer of invadopodia formation
through Cdc42, even in the absence of Src activation and
phosphorylation of other Src substrates, such as cortactin.
Thus, these data identify a novel mechanism by which
Vav1 can enhance the tumorigenicity and invasive potential
of cancer cells. These data suggest that Vav1 promotes the
matrix-degrading processes underlying tumor cell migration
and further, under conditions of ectopic Vav1 expression,
that Vav1 is a central regulator and major driver of invasive
matrix remodeling by pancreatic tumor cells.
Results and Discussion
Vav1 Expression Promotes Degradation of the
Extracellular Matrix
Ectopic expression of Vav1 in pancreatic cancers leads to
increased tumor cell survival, enhanced cell migration, and a
poor prognosis [2, 3]. Accordingly, RNAi-mediated depletion
of Vav1 in DanG pancreatic adenocarcinoma cells inhibited
transwell invasion (Figure 1A). In addition to upregulating
migratory signaling pathways, tumor cells degrade and
remodel the extracellular matrix (ECM) to allow for escape
from the primary tumor and metastasis. The actin cytoskeletal
changes required for migration and invasion are regulated by
Rho guanosine triphosphatases (GTPases), including Rac1,
RhoA, and Cdc42, the activation of which is controlled by gua-
nine nucleotide exchange factors (GEFs) [6, 7]. As Vav1 is a
GEF and activator of Rho GTPases, and is ectopically ex-
pressed in tumor cells, we hypothesized that Vav1 could*Correspondence: mcniven.mark@mayo.edupromote the invasive process of matrix degradation (Fig-
ure S1A available online) [7]. To test this, DanG cells were
depleted of Vav1 using siRNA, then plated on fluorescent
gelatin-coated coverslips for 7 hr. Control transfected cells
showed robust matrix degradation (Figure 1B). However,
Vav1depletion, confirmedbywestern blot analysis (Figure 1C),
reduced both the number of cells competent to degradematrix
(Figure 1D) and the area of degradation per cell (Figure 1E).
Similar results were observed in three other Vav1-expressing
pancreatic tumor cell lines (CFPAC, Panc04.03, and HPAF-II;
Figures S1B–S1E). Thus, in addition to regulating tumor cell
survival and migration, Vav1 also promotes degradation of
the ECM by pancreatic cancer cells.
Tumor cells degrade the ECM through invadopodia, invasive
protrusions that are sites for targeted secretion of metallo-
proteases [8]. Invadopodia consist of an actin core and require
the activity of Cdc42 for the actin nucleation and polymeriza-
tion necessary for their formation. We hypothesized that
Vav1 was required for either the formation or the maturation
of invadopodia. To test this, DanG cells were depleted of
Vav1 by siRNA, plated on fluorescent gelatin, and then stained
for actin or cortactin. Control cells formed numerous puncta,
which stained positive for both actin and cortactin, and often
coincided with sites of matrix degradation, indicating the
presence of functional invadopodia. However, depletion of
Vav1 dramatically reduced the number of actin puncta (Fig-
ure 1F). These data suggest that when Vav1 is ectopically
expressed in pancreatic tumor cells, it promotes ECM degra-
dation through the formation of invadopodia.
Vav1 Regulates Invadopodia Formation and Matrix
Degradation through Cdc42
While Vav1 is an exchange factor for Rho family GTPases, it
does have GEF-independent adaptor functions [9, 10]. Thus,
we tested if matrix degradation required Vav1 GEF activity.
Re-expression of wild-type (WT) Vav1 completely rescued
matrix degradation in the Vav1 knockdown cells (Figures 1G
and 1H). However, GEF-inactive Vav1 L278Q was unable to
restore matrix degradation, demonstrating that the GEF activ-
ity of Vav1 is required and suggesting that Vav1 regulates ECM
degradation through its action as an exchange factor for Rho
GTPases.
Vav1 is primarily a GEF for Rac1, though it also has ex-
change activity toward Cdc42 and RhoA [11, 12]. Therefore,
we sought to determine which Rho GTPase mediated matrix
degradation downstream of Vav1 in pancreatic cancer cells.
Expression of a constitutively active form of Rac1, Cdc42,
or RhoA should overcome the requirement for a GEF and
restore matrix degradation in cells depleted of Vav1. Vav1-
depleted DanG cells were transfected with empty vector or
active Rac1 (Q61L), RhoA (Q63L), or Cdc42 (Q61L). Only
expression of active Cdc42, but not Rac1 or RhoA, restored
matrix degradation in Vav1 knockdown cells, both in the
percentage of cells degrading matrix and in the area of degra-
dation per cell, suggesting that Cdc42 activation is down-
stream of Vav1 (Figures 2A–2C). Even though Vav1 regulates
Rac1 activity, matrix degradation did not require Rac1, as
knockdown of Rac1 did not affect the ability of Cdc42 to
rescuematrix degradation in Vav1-depleted cells (Figure S2A).
Figure 1. Vav1 Expression Promotes Matrix Degradation by Pancreatic Tumor Cells
(A) Vav1 is required for invasive migration of pancreatic tumor cells. DanG cells were transfected with siRNA against Vav1 or a control siRNA and plated in a
transwell invasion assay. The percentage of cells invaded across the filter after 72 hr was measured.
(B) Depletion of Vav1 using siRNA inhibits degradation of a gelatin matrix. DanG cells were transfected with siRNA against Vav1 or a control siRNA and then
plated on fluorescent gelatin for 7 hr. Cells were stained with TRITC-Phalloidin and cortactin to detect the actin cytoskeleton and invadopodial puncta.While
control cells degraded substantial amounts of matrix, the cells treated to reduce Vav1 levels did not.
(C) Parallel samples from (B) were lysed and immunoblotted to confirm protein knockdown.
(D) The percentage of cells degrading the gelatin matrix was scored. At least 100 cells were scored per condition.
(E) The area of degradation was quantified in at least 20 cells per condition.
(F) The number of actin puncta per cell was scored (n > 100 cells per condition).
(G) The GEF activity of Vav1 is required for matrix degradation. DanG cells were depleted of Vav1 using siRNA and then transfected with WT Vav1 or GEF-
inactive Vav1 (L278Q). Cells were plated on fluorescent gelatin for 7 hr, stained for ectopic Vav1 expression (not shown), and then scored for matrix degra-
dation. Re-expression of WT Vav1, but not GEF-inactive Vav1, restored matrix degradation. Asterisks indicate transfected cells. vec, empty vector.
(H) The percentage of cells degrading the gelatin matrix was scored (n > 100 cells per condition).
All graphed data indicate the mean6 SEM of at least three independent experiments. *p < 0.05; **p < 0.01. Scale bars represent 10 mm. See also Figure S1.
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Cdc42, as expression of constitutively active Cdc42 also
restored the presence of actin puncta in Vav1 knockdown
cells (Figures 2D and S2B). Consistent with this observation,
expression of dominant-negative Cdc42 (T17N) or siRNA-
mediated knockdown of Cdc42 inhibited matrix degradation
(Figures 2E and S2C) [5]. These data suggest that Vav1-medi-
ated Cdc42 activation promotes invadopodia function and
matrix degradation.
Further, RNAi-mediated depletion of Vav1 in DanG cells
reduced Cdc42 activation by 60% in pancreatic cancer cells,
as measured by a biochemical pull-down for active Cdc42
(Figure 2F). In addition, overexpression of WT Vav1, but not
GEF-inactive Vav1 L278Q, caused a 2-fold increase in Cdc42
activation in PANC1 pancreatic cancer cells (which do notexpress endogenous Vav1, Figure 2G). Taken together, these
data indicate that Vav1 regulates matrix degradation in
pancreatic cancer cells through activation of Cdc42.
Vav1 Mediates the Effects of Src on Matrix Degradation
The tyrosine kinase Src is aberrantly activated inmany cancers
and is a potent inducer of invadopodia formation and matrix
degradation [13–15]. Src family kinases phosphorylate multi-
ple substrates involved in invadopodial structure and dy-
namics, including neural Wiskott-Aldrich syndrome protein
(N-WASP), cortactin, the scaffold Tyrosine kinase substrate
5 (Tks5), and the phosphatidylinositol 5-phosphatase synap-
tojanin 2 (PI) [15–20]. Vav1 is a substrate for Src family kinases
in hematopoietic cells, where phosphorylation of critical resi-
dues (Tyr142, Tyr160, and Tyr174) induces a conformational
Figure 2. Vav1 Regulates Matrix Degradation through Cdc42
(A) Constitutively active Cdc42, but not constitutively active Rac1 or RhoA, rescues matrix degradation in Vav1 knockdown cells. DanG cells were depleted
of Vav1 by siRNA and then transfected withmyc-taggedRac1 (Q61L), RhoA (Q63L), or Cdc42 (Q61L). Cells were plated on a fluorescent gelatinmatrix for 7 hr
and then fixed and stained for the myc epitope tag (not shown).
(B and C) The percentage of cells degrading the gelatin matrix was scored (n > 100 cells per condition) (B), and the area of degradation was quantified (n > 20
cells per condition) (C).
(D) Cells transfected as described above were stained for actin and themyc epitope tag (not shown), and the number of actin puncta per cell was scored (n >
40 cells per condition).
(E) Dominant-negative Cdc42 inhibits matrix degradation in Vav1-expressing cells. DanG cells were transfected with empty vector or Cdc42 T17N, and
matrix degradation was assessed as described. Cdc42 T17N expression was verified by immunofluorescence for Cdc42 (not shown). The percentage of
cells degrading matrix was scored in at least 50 cells per condition.
(F) Cdc42 activation is impaired in the absence of Vav1. DanG cells were depleted of Vav1 by siRNA and subjected to a glutathione S-transferase (GST)-p21-
activated kinase binding domain (PBD) pull-down for active Cdc42.
(G) Ectopic Vav1 expression enhances Cdc42 activation. PANC1 cells were transfected with empty vector, WT Vav1, or GEF-inactive Vav1 (L278Q) and were
analyzed by GST-PBD pull-down for active Cdc42.
For both (F) and (G), levels of active Cdc42 were normalized to total Cdc42.
All graphed data indicate the mean 6 SEM of at least three independent experiments. *p < 0.05; **p < 0.01; ns, no statistically significant difference. Scale
bars represent 10 mm. See also Figure S2.
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88change to allow activation of Vav1 [21–24]. Mutation of Vav1 to
mimic its activated phosphorylated state increases Rac1 acti-
vation and migration in breast cancer cells [25]. Therefore, wehypothesized that Src signals through Vav1 in pancreatic
tumor cells to modulate invadopodia formation and matrix
degradation. Vav1 is phosphorylated downstream of Src in
Figure 3. Src-Mediated Activation of Vav1 Is a Central Regulator of Matrix Degradation by Pancreatic Tumor Cells
(A) Vav1 is phosphorylated downstream of Src family kinases in pancreatic tumor cells. DanG cells were treated with PP2 (25 mM) for 4 hr, then stimulated
with EGF (100 ng/ml) for 5 min. Lysates were immunoprecipitated (IP) for Vav1 and immunoblotted for phosphotyrosine. PP2 treatment abolished Vav1 tyro-
sine phosphorylation.
(B) Vav1 is required for Src-mediated matrix degradation. DanG cells depleted of Vav1 were transfected with dsRed vector or dsRed-tagged active Src
(Y530F) and plated on fluorescent gelatin for 7 hr. The asterisk indicates a transfected cell. The percentage of cells degrading matrix was scored in >50 cells
per condition. Even in the presence of active Src, cells depleted of Vav1 do not degrade the gelatin matrix.
(C) Themutation R696A blocks Vav1 phosphorylation. PANC1 cells were transfected with control vector, WT Vav1, or Vav1 R696A, stimulated with EGF, and
processed as described in (A). Tyrosine phosphorylation of Vav1 was severely inhibited by the R696A mutation.
(D) Vav1 phosphorylation and activation regulate Cdc42. PANC1 cells were transfectedwithWT Vav1, active Vav1 (Y174F), or Vav1 R696A and subjected to a
GST-PBD pull-down. Active Cdc42 was normalized to total Cdc42 and compared to cells expressing WT Vav1.
(E) Vav1 activation is required formatrix degradation. DanG cells were depleted of Vav1 by siRNA, then transfected to express eitherWT Vav1 or Vav1 R696A
and plated on fluorescent gelatin for 7 hr. The percentage of cells capable of degrading the matrix was scored in >50 cells per condition. WT Vav1 rescued
matrix degradation, but not Vav1 R696A.
All graphed data represent the mean 6 SEM of three independent experiments. *p < 0.05; **p < 0.01; ns, no statistically significant difference. Scale bars
represent 10 mm. See also Figure S3.
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89DanG cells, as epidermal growth factor (EGF)-stimulated tyro-
sine phosphorylation of Vav1 was inhibited by the Src inhibi-
tors PP2 or dasatinib (Figures 3A and S3A). Consistently,
Vav1 tyrosine phosphorylation was increased 2-fold by
expression of active Src Y530F, but not inactive Src Y419F
(Figure S3B). Together, these data suggest that Src family
kinases promote Vav1 tyrosine phosphorylation and, there-
fore, Vav1 activation.
To test if Vav1 is required for Src-mediated matrix remodel-
ing, DanG cells were transfected with constitutively active Src
(Y530F) and then depleted of Vav1 by siRNA. Remarkably,
matrix degradation in the Src-expressing cells was almost
completely ablated in theabsenceofVav1 (Figure3B), suggest-
ing that Vav1 functions downstream of Src to support matrixremodeling. As DanG cells have high levels of active Src and
matrix degradation, additional expression of active Src did
not increase matrix remodeling. Significantly, in Panc04.03
cells, which have lower levels of endogenous matrix degrada-
tion, expression of active Src Y530F caused a 3-fold increase
in matrix degradation, which was completely blocked by
knockdown of Vav1 (Figure S3C). Together, these data indicate
a requirement for Vav1 in Src-mediated matrix degradation.
We next tested if Src-mediated phosphorylation and activa-
tion of Vav1 were required for matrix degradation by prevent-
ing Vav1 phosphorylation. Paradoxically, structural studies
have determined that the Y174F mutation induces the open,
‘‘active’’ conformation, even in the absence of a phosphate,
inducing constitutive activation [26, 27]. Therefore, an indirect,
Figure 4. Vav1 Activation Is Sufficient for Matrix Degradation Downstream of Src
(A) DanG cells were transfected with control vector or active Vav1 Y174F, then treatedwith the Src inhibitor PP2 (10 mM) or DMSO vehicle control while plated
on a fluorescent gelatin matrix for 7 hr.
(B) The percentage of cells degrading the matrix was scored (n > 100 cells per condition).
(C) The area of degradation was quantified in >20 cells per condition. Note that Vav1 Y174F potently induced matrix degradation, even in the presence
of PP2.
(D) Vav1 Y174F rescues the formation of invadopodia. DanG cells were transfected as described in (A) and plated on fluorescent gelatin overnight in the
presence of BB94 (1 mM). The BB94 was washed out, and cells were incubated for 4 hr with or without PP2 prior to staining for actin to mark invadopodia
and Vav1 to detect transfected cells (not shown).
(E) The number of actin puncta per cell was scored in at least 20 cells per condition.
(F) Vav1 Y174F can be detected at sites ofmatrix degradation. DanG cells were transfectedwith Vav1 Y174F andplated on fluorescent gelatin (green) for 7 hr.
Cells were fixed and stained for Vav1 (red). The boxed regions are magnified at right. Arrows indicate Vav1 Y174F puncta that colocalize with sites of matrix
degradation.
(legend continued on next page)
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91inactive Vav1 form was used by mutating the Src homology 2
(SH2) domain of Vav1 (R696A), which impairs its ability to
interact with tyrosine-phosphorylated substrates required for
Vav1 recruitment and activation by Src [28]. Consistent with
a defect in recruitment and activation, Vav1 R696A is not
tyrosine phosphorylated in EGF-stimulated cells (Figure 3C).
Further, Vav1 phosphorylation and activation correspond
with an ability to activate Cdc42. PANC1 cells transfected to
express WT Vav1, active Vav1 Y174F, or phosphorylation-
deficient Vav1 R696A showed marked differences in Cdc42
activation. Cells expressing phosphorylation-defective, inac-
tive R696A Vav1 exhibited much less activation than cells
expressing WT Vav1 (Figure 3D), whereas active Vav1 Y174F
induced a 2-fold increase in Cdc42 activation compared to
WT Vav1. These data suggest that Vav1 phosphorylation and
activation downstream of Src family kinases regulate Cdc42
activation in pancreatic cancer cells.
We then tested if phosphorylation of Vav1 controls matrix
degradation. Notably, the defect in matrix degradation
induced by Vav1 knockdown was completely rescued by re-
expression of WT Vav1, but not the R696A mutant (Figure 3E),
suggesting that Vav1 recruitment and phosphorylation are
required for Cdc42-mediated degradation of the ECM.
Vav1-Cdc42 Activation Is Sufficient for Matrix Degradation
Downstream of Src
From these findings, we hypothesized that Vav1 phosphoryla-
tion alone could be sufficient to induce invadopodia formation
and matrix degradation downstream of Src. Thus, expression
of an active Vav1 could potentially drive matrix degradation,
even when Src activity is ablated by a Src inhibitor. The Src
inhibitor PP2 blocked matrix degradation in control cells
(Figures 4A–4C). While expression of the active Vav1 Y174F
markedly enhanced matrix degradation in control cells, most
remarkable was that PP2-treated cells exhibited the same
massive increase in degradation. Similar results were
observed in the presence of the Src inhibitors SU6656 and
dasatinib, and in CFPAC cells (Figures S4A–S4C). Similarly,
PP2 treatment inhibited the formation of invadopodia, and
this defect was rescued by expression of Vav1 Y174F (Figures
4D and 4E). Thus, even in the presence of a Src inhibitor,
activation of Vav1 induces degradation of the matrix, suggest-
ing that Vav1 activation is sufficient for invadopodial matrix
degradation downstream of Src.
Consistent with these findings, active Vav1 Y174F showed
increased localization to sites of matrix degradation and to
actin puncta marking invadopodia compared to cells express-
ing WT Vav1. Importantly, the Src inhibitory drug PP2 did not
reduce this colocalization (Figures 4F and S4D). We speculate
that Vav1 localization is transient or occurs only at early stages
of invadopodia formation. These stages may then be
enhanced by the constitutive activation of Vav1 using the
Y174F mutation, thereby facilitating Vav1 detection at these(G) DanG cells virally transduced to stably express Vav1 Y174F were transfecte
plated on fluorescent gelatin in the presence of 10 mMPP2. Overexpressed Vav1
respectively (not shown). Cdc42 T17N inhibits matrix degradation induced by
(H) DanG cells were transfected with myc-tagged active Cdc42 (Q61L) or empty
Cdc42Q61L expressionwas verified by anti-myc immunofluorescence (not sho
of PP2. For (E) and (F), the percentage of cells degrading matrix was scored in
(I) The Src substrate cortactin is not phosphorylated upon PP2 treatment. Dan
(10 mM) or DMSO control, then immunoprecipitated for cortactin and blotted
treated cells, even in the cells expressing Vav1 Y174F.
All graphed data represent the mean 6 SEM of three independent experiment
represent 10 mm. See also Figure S4.sites. The localization of Vav1 Y174F to sites of matrix
degradation supports the premise that Vav1 is a component
of invadopodial assembly, and further, our data suggest that
Vav1 activation is dominant to upstream Src-mediated
signaling pathways.
We sought to confirm that this Src-independent degradation
was in fact mediated through Vav1-induced Cdc42 activation,
as shown above (Figure 2). Expression of dominant-negative
Cdc42 (T17N) or siRNA-mediated knockdown of Cdc42
markedly reduced the degradation induced by Vav1 Y174F
in PP2-treated DanG cells (Figures 4G and S4E). Taken
together, these data indicate that Cdc42 is necessary down-
stream of active Vav1 to promote matrix degradation down-
stream of Src.
As an extension of these findings, we predicted that Vav1
Y174F should promote Cdc42 activation, even in the presence
of the Src inhibitor. While this activation was observed, we
also found an unexpected activation of Cdc42 following PP2
treatment in both control cells and cells expressing Vav1
Y174F. Even though Vav1 potently regulates Cdc42 activation
(Figure 2), this suggests that Cdc42 activity could also be
regulated by other Src-dependent factors as Vav1 would be
inactive in these cells. Further, as Src inhibitors clearly reduce
invadopodia formation (Figure 4), this finding suggests that
Cdc42 activation, while necessary, may not be sufficient for
matrix degradation downstream of Src. As an alternative
approach to this question, we tested if constitutively active
Cdc42 (Q61L) was sufficient to restore matrix degradation
even upon inhibition of Src. As observed previously, PP2
treatment inhibited matrix degradation by DanG cells, and
notably, Cdc42 Q61L was sufficient to overcome the loss of
Src activity and restore matrix degradation, similar to expres-
sion of Vav1 Y174F (Figure 4H). These data suggest that hyper-
activation of Cdc42 via mutation or expression of the mutant
GEF is sufficient for matrix degradation downstream of Src.
While we cannot exclude that Vav1 and Cdc42 may act in
parallel pathways, our data do support the model that Src-
mediated activation of Vav1 drives Cdc42 activity, which is
then sufficient for invadopodia formation and matrix degrada-
tion. Cdc42 promotes invadopodia formation by signaling
through N-WASP and Arp2/3 to induce actin nucleation and
branching [29, 30]. It remains to be determined if Cdc42
promotes matrix degradation solely through the defined
N-WASP-Arp2/3 pathway or if other downstream effectors
are also required.
Unexpectedly, this finding suggests that phosphorylation of
other Src substrates may not be required for invadopodia
formation. Therefore, we wanted to test the phosphorylation
of cortactin, a known substrate downstream of Src via Arg/
Abl involved in invadopodia formation [31], in Vav1 Y174F-
expressing cells treated with a Src inhibitor. If cortactin was
not phosphorylated, it would suggest that active Vav1 could
induce invadopodia-mediated matrix degradation even ind with empty vector or dominant-negative Cdc42 (T17N, myc tagged), then
and Cdc42 T17Nwere identified by immunofluorescence for Vav1 andmyc,
Vav1 Y174F.
vector and plated on fluorescent gelatin with or without PP2 (10 mM) for 7 hr.
wn). Cdc42Q61Lwas sufficient to rescuematrix degradation in the presence
at least 50 cells per experiment.
G cells stably expressing GFP vector or Vav1 Y174F were treated with PP2
for phosphotyrosine. Note that cortactin is not phosphorylated in the PP2-
s. *p < 0.05; **p < 0.01; ns, no statistically significant difference. Scale bars
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92the absence of cortactin phosphorylation. In control cells, PP2
treatment blocked tyrosine phosphorylation of cortactin, con-
firming that it is phosphorylated downstream of Src (Figure 4I).
Importantly, cortactin phosphorylation was unaffected by the
Vav1 Y174F mutation. Cortactin phosphorylation was blocked
by PP2 treatment even in cells expressing Vav1 Y174F, which
form invadopodia and potently degrade the matrix. These
data demonstrate that active Vav1 drives invadopodia-medi-
ated matrix degradation, even in the absence of Src activation
and phosphorylation of a known substrate. Further, the data
suggest that Src phosphorylation of cortactin may be
dispensable for matrix degradation in tumor cells with acti-
vated Vav1. Perhaps Cdc42-driven N-WASP activation is
sufficient, and further enhancement regulated by cortactin
phosphorylation is not necessary. Alternatively, a recent
report described phosphorylation-independent interactions
between cortactin and SH2 domains of its binding partners,
suggesting that cortactin phosphorylation may not be
required for its effects [32].
These data strongly support a central role for Vav1 in
promoting invadopodia and matrix degradation. Pancreatic
cancer cell lines that express Vav1 have become dependent
upon it as knockdown of Vav1 inhibits matrix degradation,
even in the presence of multiple other Cdc42 GEFs. However,
while Vav1 is ectopically expressed in many pancreatic can-
cers, it is not expressed in all tumor cells (Figure S1B), some
of which are still able to form invadopodia and degradematrix.
We hypothesize that Vav1-negative tumors and tumor cell
lines have upregulated the invadopodial and invasive machin-
ery by other mechanisms, such as a different Cdc42 GEF.
Accordingly, we screened a panel of nine pancreatic cancer
cell lines for the expression of six different Cdc42 GEFs, and
consistent with our prediction, nearly every tumor cell line
exhibited a different pattern of GEF expression (Figure S4F).
These data reflect the heterogeneity of tumors among individ-
uals and strengthen the case for an individualized approach to
cancer treatment. We hypothesize that differential expression
of GEFs is important for defining the pathway regulating
invadopodia formation in specific cell types. It will be key to
determine how/why different GEFs are utilized (either indepen-
dently or in combination) and how converging signals may
activate one or more GEFs selectively.
Activating mutations in Vav1 have not been described in
pancreatic cancers. However, pathways that lead to Vav1
phosphorylation and activation are known to be hyperacti-
vated, including EGF receptor and Src [13]. Therefore, it is
highly likely that in tumors where Vav1 is ectopically
expressed, its activation is upregulated due to hyperactivation
of regulatory signaling pathways. Thus, activation of any
pathway leading to activation of Src family kinases or, ulti-
mately, Vav1, could potently upregulate the invasive machin-
ery. In addition, while some of the Src inhibitors used in this
study have additional kinase targets, this only strengthens
the importance of active Vav1 and describes it as a more
global regulator of matrix degradation downstream of multiple
signaling pathways.
We have recently reported that Vav1 is required for Rac1-
mediated formation of lamellipodia and subsequent migration
of tumor cells [3]. In addition, Vav1 is a potent regulator of
transendothelial migration of leukocytes and also contributes
to CXCL12-induced MT1-matrix metalloprotease (MMP)
expression and invasion by melanoma cells [33, 34]. The
current findings further implicate Vav1 in the processes of
invasion and migration, namely through the formation ofinvadopodia and matrix degradation. This process requires
Vav1 activation of Cdc42, demonstrating that in pancreatic
tumor cells, ectopically expressed Vav1 can signal through
multiple pathways. This is consistent with a previous report
that Vav1-induced oncogenic transformation requires multiple
signaling pathways, including Rac1, Cdc42, and RhoA, as well
as nuclear factor kB (NF-kB) and Jun-N-terminal kinase (JNK)
[35]. Indeed, these data implicate Vav1 inmultiple stages of the
tumorigenic and metastatic program and suggest that upon
its aberrant expression, Vav1 is a pivotal signaling node in
pancreatic cancers.
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